Search 

The NIHR works in partnership with SMEs, life science companies and CROs to design and deliver research within the UK health and social care environment. From early stage, translational research through to later stage clinical trials, a full range of free support is available.  We offer:

• Access to world-leading academic and clinical expertise, collaborations and partnerships.

• Support to rapidly determine if your study is compatible with UK clinical practice.

• Help to effectively and efficiently plan, place and perform your research.

• Support in accessing funding, data and clinical samples.

• Help to engage patients to improve your study design and optimise recruitment and retention.

• Assistance to help you navigate the UK health and research system.

Nevrargenics Ltd is a UK-based neuroscience company specialising in the discovery and development of novel medicines for the treatment of neurodegenerative disease, such as Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Alzheimer’s, Parkinson’s, Multiple Sclerosis and other neurological diseases as well as application in other conditions such as liver diseases and eye diseases.

A new class of drugs to block and reverse neurodegeneration and other conditions such as liver diseases:  Unique, dual-acting retinoic acid receptor modulators.  Our drug candidates have shown selective binding to Retinoic Acid Receptors (RARs), with high activity for neuroprotection and neuroregeneration at exceptionally low doses.